Back to library
Weight Management

Tirzepatide

A dual GIP and GLP-1 receptor agonist offering powerful weight loss and metabolic benefits. DO NOT combine with Semaglutide or other GLP-1 agonists.

10 mg vialHalf-life: 5 daysOnce weeklyHigh-conc · ≤20 mg/mL
Order: Coming soon

Overview

Clinical Benefits
  • Superior weight loss
  • Blood sugar control
  • Reduced appetite
  • Improved metabolic markers
Administration

Subcutaneous injection — abdomen, thigh, or upper arm

Drug class: glp1 gip dual agonist

Clinical Dosing

Typical dosage
2.5mg starting, titrate up to 15mg
Starting dose
2.5mg
Cadence
Once weekly
Full titration schedule
PhaseDose
Weeks 1-42.5mg once weekly
Weeks 5-85mg once weekly
Weeks 9-127.5mg once weekly
Weeks 13-1610mg once weekly
Weeks 17+12.5-15mg once weekly (maintenance)

Safety Profile

Side effects
  • • Nausea (most common at dose increases)
  • • Diarrhea
  • • Vomiting
  • • Decreased appetite
Contraindications
  • • Medullary thyroid carcinoma
  • • MEN 2 syndrome
Do not combine with

Frequently asked questions

Tirzepatide is most commonly researched for: Superior weight loss, Blood sugar control, Reduced appetite, Improved metabolic markers.

Ready to build a protocol with Tirzepatide?

LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.

You’ll be asked to sign in first. Free tier includes the chat preview.

Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.

Add to Home Screen

Install PeptideAI for quick access and an app-like experience.